TLR7 and cancer: MUC-1 and toll-like receptor 7 (TLR-7) peptide in a murine model of BC were tested, and this vaccine induced CTL response and antibody-dependent cellular cytotoxicity (ADCC) and improved humoral immunity against MUC-1 + cancer cells [61].